Evidence map›Paper›PMID 40500586›Full record

Observational studyJapanese journal of ophthalmology2025

En-face quantitative evaluation using ultra-high-resolution OCT of hyperreflective foci in neovascular age-related macular degeneration.

Iori Wada, Shintaro Nakao, Satomi Shiose, Yoshihiro Kaizu, Muneo Yamaguchi, Keijiro Ishikawa, Kohei Kiyohara, Tatsuro Ishibashi, Koh-Hei Sonoda

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Japanese journal of ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Iori WadaDepartment of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Shintaro NakaoDepartment of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. s.nakao.dk@juntendo.ac.jp.ORCID http://orcid.org/0000-0003-4200-0052
Satomi ShioseDepartment of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Yoshihiro KaizuDepartment of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Muneo YamaguchiDepartment of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Keijiro IshikawaDepartment of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Kohei KiyoharaDepartment of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Tatsuro IshibashiDepartment of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Koh-Hei SonodaDepartment of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Funding

JSPS KAKENHI 20K09829
6 · The paper itself

Abstract

purposeThis study quantifies hyperreflective foci (HRFs) in neovascular age-related macular degeneration (nAMD) before and after anti-VEGF therapy in the initial loading phase using en-face ultra-high-resolution spectral domain OCT (UHR-SD-OCT), investigating their correlation with clinical findings. STUDY

designRetrospective observational study

methodsThis retrospective study included 30 eyes from 30 patients with treatment-naïve nAMD. The patients received monthly intravitreal injections of anti-VEGF therapy for three months as the initial loading phase. At each visit, comprehensive ophthalmic examinations were conducted. HRFs were quantified using our custom-developed software from an en-face UHR-SD-OCT. The number of HRFs was compared before and after the loading phase and investigated the relationship with best-corrected visual acuity (BCVA), greatest linear dimension (GLD), macular neovascularization (MNV) size and incidence of macular atrophy (MA).

resultsThis evaluation system showed a significant reduction in the number of HRFs after anti-VEGF therapy compared to before the loading phase (p < 0.0001). The number of pre-treatment HRFs significantly correlated with pre-treatment BCVA, GLD, and MNV size. The number of post-treatment HRFs significantly correlated with pre-treatment GLD and pre-treatment MNV size. Additionally, patients who developed MA two years after treatment initiation exhibited significantly higher counts of pre-treatment HRFs compared to those without the MA development (465.7 ± 187.0 vs. 212.9 ± 93.8, p < 0.05).

conclusionsQuantification of HRF using en-face UHR-SD-OCT may be a useful clinical biomarker during anti-VEGF therapy in nAMD.

Indexed as

Macula LuteaTomography, Optical CoherenceVisual AcuityWet Macular DegenerationAgedAged, 80 and overAngiogenesis InhibitorsBevacizumabFemaleFluorescein AngiographyFollow-Up StudiesFundus OculiHumansIntravitreal InjectionsMaleRanibizumabAngiogenesis InhibitorsBevacizumabRanibizumabVascular Endothelial Growth Factor AMacular atrophyNew treatment indexTreatment strategy

Identifiers

PMID40500586

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.